中国癌症杂志2025，Vol.35Issue(10)：935-940,6.DOI:10.19401/j.cnki.1007-3639.2025.10.005
晚期分化型甲状腺癌系统治疗的10年演进:2015与2025年版ATA指南对比分析
The ten-year evolution of systemic therapy for advanced differentiated thyroid cancer:a comparison between the 2015 and 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
摘要
Abstract
Differentiated thyroid carcinoma(DTC)generally has a favorable prognosis.Most patients with DTC achieve good outcomes with surgery combined with radioactive iodine(RAI)therapy,with a 10-year survival rate exceeding 90%.However,about 5%-10%of patients develop unresectable local disease or distant metastases during the course of treatment,and may even gradually progress to a radioiodine-refractory(RAIR)state.For these advanced and inoperable patients,traditional treatments are difficult to control disease progression,making systemic drug therapy the mainstay of treatment.Over the past decade,significant advances in molecular targeted therapy and immunotherapy have transformed the landscape of advanced DTC.The2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer(abbreviation ATA guideline)propose a precision treatment model centered on molecular subtyping.This article compares the main differences in systemic therapy for advanced DTC between the 2015 and 2025 ATA guidelines,and,by integrating key clinical trials and real-world data,analyzes the evolution of treatment strategies over the past ten years and future directions.关键词
晚期分化型甲状腺癌/靶向治疗/免疫治疗/药物不良反应Key words
Advanced differentiated thyroid cancer/Target therapy/Immunotherapy/Adverse events分类
医药卫生引用本文复制引用
杨舒雯,季冬梅,王宇..晚期分化型甲状腺癌系统治疗的10年演进:2015与2025年版ATA指南对比分析[J].中国癌症杂志,2025,35(10):935-940,6.基金项目
国家自然科学基金(82473361) （82473361）
中华人民共和国科学技术部四大慢病重大专项(2024ZD0525600). National Natural Science Foundation of China General Program(82473361) （2024ZD0525600）
Major Special Project for Four Chronic Diseases under the Ministry of Science and Technology of the People's Republic of China(2024ZD0525600). （2024ZD0525600）
